Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of therapies for debilitating liver diseases. Co.'s pipeline consists of product candidates with mechanisms of action that have potential utility across a range of orphan cholestatic liver diseases. Co. is developing maralixibat for the treatment of pediatric patients with Alagille syndrome and progressive familial intrahepatic cholestasis. Maralixibat and volixibat are investigational, oral, minimally-absorbed agents designed to inhibit the apical sodium-dependent bile acid transporter, which is responsible for recycling bile acids from the intestine to the liver. The MIRM stock yearly return is shown above.
The yearly return on the MIRM stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the MIRM annual return calculation with any dividends reinvested as applicable (on ex-dates).
|